Literature DB >> 25801741

Substantial clinical benefit of minimally invasive lateral interbody fusion for degenerative spondylolisthesis.

Kaveh Khajavi1, Alessandria Shen, Anthony Hutchison.   

Abstract

PURPOSE: Conventional lumbar arthrodesis for the treatment of degenerative spondylolisthesis (DS) is associated with high complication rates and variable clinical efficacy. Modern minimally invasive (MIS) approaches may reduce the morbidity and produce greater clinical improvement compared to traditional surgical techniques. The objective of this study is to report radiographic outcomes and evaluate clinical improvements in the context of substantial clinical benefit for DS patients treated with a MIS 90° lateral, transpsoas approach for lumbar interbody fusion.
METHODS: From 2005 to 2011, 60 consecutive patients were treated with MIS lateral interbody fusion for Grade I or II DS at a single institution. Mean patient age was 68 years, 75 % were female, and 30 % had undergone previous lumbar surgery. A total of 71 levels were treated, supplemental posterior fixation was used in 57 (95 %) cases, and 26 (43 %) patients underwent additional direct posterior decompression.
RESULTS: Average follow-up was 20.3 months. Average ORT, EBL, and LOS were 206 min, 83 cc, and 1.29 days, respectively. Complications occurred in 3 (5 %) patients. Transient approach-related thigh/groin pain was observed in 5 (8 %) cases. There were no cases of pseudoarthrosis. At 1 year, LBP improved 71 %, LP improved 68 %, ODI decreased 52 %, and SF-36 PCS and MCS improved 43 and 21 %, respectively. Substantial clinical benefit was met by 94.7 % of patients on NRS LBP, by 84.6 % on NRS LP, by 83.7 % on ODI, and by 66.7 % on SF-36 PCS. Disc height increased 71 % and segmental lordosis increased 27.8 % at treated levels. Foraminal height, width, and volume increased 19.7, 18.0, and 39.6 %, respectively. Slip improved 60.7 % with interbody fusion only and further improved to 69.2 % after the placement of supplemental instrumentation.
CONCLUSIONS: MIS lateral interbody fusion in the treatment of DS resulted in significant improvements in clinical and radiographic outcomes, with a low complication rate and a high proportion of patients achieving substantial clinical benefit.

Entities:  

Mesh:

Year:  2015        PMID: 25801741     DOI: 10.1007/s00586-015-3841-1

Source DB:  PubMed          Journal:  Eur Spine J        ISSN: 0940-6719            Impact factor:   3.134


  50 in total

1.  Intraoperative and early postoperative complications in extreme lateral interbody fusion: an analysis of 600 cases.

Authors:  W Blake Rodgers; Edward J Gerber; Jamie Patterson
Journal:  Spine (Phila Pa 1976)       Date:  2011-01-01       Impact factor: 3.468

2.  A radiographic assessment of the ability of the extreme lateral interbody fusion procedure to indirectly decompress the neural elements.

Authors:  Leonardo Oliveira; Luis Marchi; Etevaldo Coutinho; Luiz Pimenta
Journal:  Spine (Phila Pa 1976)       Date:  2010-12-15       Impact factor: 3.468

3.  Minimally invasive lateral transpsoas approach with advanced neurophysiologic monitoring for lumbar interbody fusion.

Authors:  Pedro Berjano; Claudio Lamartina
Journal:  Eur Spine J       Date:  2011-09       Impact factor: 3.134

4.  Retrograde ejaculation after retroperitoneal lower lumbar interbody fusion.

Authors:  F B Christensen; C E Bünger
Journal:  Int Orthop       Date:  1997       Impact factor: 3.075

Review 5.  Far lateral approaches (XLIF) in adult scoliosis.

Authors:  Pedro Berjano; Claudio Lamartina
Journal:  Eur Spine J       Date:  2012-07-27       Impact factor: 3.134

Review 6.  Anterior-only approaches to scoliosis.

Authors:  Mohammed F Shamji; Robert E Isaacs
Journal:  Neurosurgery       Date:  2008-09       Impact factor: 4.654

7.  The impact of perioperative complications on clinical outcome in adult deformity surgery.

Authors:  Steven D Glassman; Christopher L Hamill; Keith H Bridwell; Frank J Schwab; John R Dimar; Thomas G Lowe
Journal:  Spine (Phila Pa 1976)       Date:  2007-11-15       Impact factor: 3.468

8.  Complications associated with single-level transforaminal lumbar interbody fusion.

Authors:  Jeffrey A Rihn; Ravi Patel; Junaid Makda; Joseph Hong; David G Anderson; Alexander R Vaccaro; Alan S Hilibrand; Todd J Albert
Journal:  Spine J       Date:  2009-05-30       Impact factor: 4.166

9.  Mini-open approach to the spine for anterior lumbar interbody fusion: description of the procedure, results and complications.

Authors:  Salvador A Brau
Journal:  Spine J       Date:  2002 May-Jun       Impact factor: 4.166

10.  Stand-alone lateral interbody fusion for the treatment of low-grade degenerative spondylolisthesis.

Authors:  Luis Marchi; Nitamar Abdala; Leonardo Oliveira; Rodrigo Amaral; Etevaldo Coutinho; Luiz Pimenta
Journal:  ScientificWorldJournal       Date:  2012-04-01
View more
  15 in total

1.  The Michel Benoist and Robert Mulholland yearly European spine journal review: a survey of the "surgical and research" articles in the European spine journal, 2015.

Authors:  Robert C Mulholland
Journal:  Eur Spine J       Date:  2016-01-05       Impact factor: 3.134

2.  A radiographic analysis of cage positioning in lateral transpsoas lumbar interbody fusion.

Authors:  Timothy L T Siu; Elmira Najafi; Kainu Lin
Journal:  J Orthop       Date:  2016-11-22

3.  Extreme lateral interbody fusion for unilateral symptomatic vertical foraminal stenosis.

Authors:  Marjan Alimi; Christoph P Hofstetter; Apostolos J Tsiouris; Eric Elowitz; Roger Härtl
Journal:  Eur Spine J       Date:  2015-04-18       Impact factor: 3.134

Review 4.  Clinical outcomes after minimally invasive transforaminal lumbar interbody fusion and lateral lumbar interbody fusion for treatment of degenerative lumbar disease: a systematic review and meta-analysis.

Authors:  Gun Keorochana; Kitipong Setrkraising; Patarawan Woratanarat; Alisara Arirachakaran; Jatupon Kongtharvonskul
Journal:  Neurosurg Rev       Date:  2016-12-24       Impact factor: 3.042

5.  Improvements in Back and Leg Pain Following a Minimally Invasive Transforaminal Lumbar Interbody Fusion.

Authors:  Dustin H Massel; Benjamin C Mayo; Ankur S Narain; Fady Y Hijji; Philip K Louie; Nathaniel W Jenkins; James M Parrish; Kern Singh
Journal:  Int J Spine Surg       Date:  2020-10

6.  The Change of Spinal Canal According to Oblique Lumbar Interbody Fusion in Degenerative Spondylolisthesis: A Prospective Observational Study.

Authors:  Young-Seok Lee; Dong-Hyun Lee; Dae-Chul Cho; Inbo Han; Chi Heon Kim; Heum-Dai Kwon; Kyoung-Tae Kim
Journal:  Neurospine       Date:  2022-05-13

7.  Major complications in extreme lateral interbody fusion access: multicentric study by Italian S.O.L.A.S. group.

Authors:  Andrea Piazzolla; Davide Bizzoca; Pedro Berjano; Massimo Balsano; Josip Buric; Stefano Carlucci; Carlo Formica; Matteo Formica; Claudio Lamartina; Corrado Musso; Francesco Tamburrelli; Marco Damilano; Fulvio Tartara; Aldo Sinigaglia; Roberto Bassani; Massimiliano Neroni; Giovanni Casero; Alessio Lovi; Diego Garbossa; Zullo Nicola; Biagio Moretti
Journal:  Eur Spine J       Date:  2020-08-03       Impact factor: 3.134

8.  Improvements in Back and Leg Pain After Minimally Invasive Lumbar Decompression.

Authors:  Dustin H Massel; Benjamin C Mayo; Dil V Patel; Daniel D Bohl; Philip K Louie; Gregory D Lopez; Kern Singh
Journal:  HSS J       Date:  2019-02-22

Review 9.  Lateral Lumbar Interbody Fusion: What Is the Evidence of Indirect Neural Decompression? A Systematic Review of the Literature.

Authors:  Matteo Formica; Emanuele Quarto; Andrea Zanirato; Lorenzo Mosconi; Davide Vallerga; Irene Zotta; Maddalena Lontaro Baracchini; Carlo Formica; Lamberto Felli
Journal:  HSS J       Date:  2020-03-20

10.  Do preoperative clinical and radiographic characteristics impact patient outcomes following one-level minimally invasive transforaminal lumbar interbody fusion based upon presenting symptoms?

Authors:  Kyle W Morse; Ram K Alluri; Avani S Vaishnav; Hikari Urakawa; Jung Kee Mok; Sohrab S Virk; Evan D Sheha; Sheeraz A Qureshi
Journal:  Spine J       Date:  2021-10-23       Impact factor: 4.297

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.